Dr Elena Elimova speaks to ecancer about the HERIZONGEA-01 trial.

In this trial, zanidatamab-based regimens significantly improved progression-free survival compared with trastuzumab plus chemotherapy in previously untreated HER2-positive metastatic gastric and gastroesophageal adenocarcinoma.

Zanidatamab combined with tislelizumab and chemotherapy also demonstrated a statistically significant and clinically meaningful overall survival benefit, with durable efficacy across key subgroups regardless of PD-L1 status.

Safety was manageable and consistent with known profiles, with no new safety signals identified.

These results support zanidatamab as a potential new first-line standard of care for HER2-positive metastatic gastroesophageal adenocarcinoma.